Wasatch Advisors takes 6.1% stake in Esperion Therapeutics (NASDAQ: ESPR)

Rhea-AI Filing Summary

Esperion Therapeutics ownership disclosure: institutional investor Wasatch Advisors reports beneficial ownership of 15,768,897 shares of Common Stock, representing 6.1% of the class. The filing shows sole voting power of 12,377,523 shares and sole dispositive power of 15,768,897. The filing is signed by Mike Yeates, CEO, dated 04/22/2026.

Insights

Institutional Ownership Analyst

Wasatch Advisors holds a notable 6.1% stake in Esperion.

Wasatch Advisors is reported to beneficially own 15,768,897 shares, representing 6.1% of outstanding common stock; sole voting power is 12,377,523 shares. This level of ownership is large enough to be visible to the market but does not by itself imply control.

Monitor future Schedule 13D/G filings or Form 4s for changes in voting intent or transactions; current excerpt gives ownership counts and power designations only.

Corporate Governance Specialist

Filing documents voting and dispositive powers separately, useful for governance analysis.

The filing lists separate metrics: sole voting power 12,377,523 and sole dispositive power 15,768,897. These labels identify who can direct votes versus who can direct sales of shares.

Stakeholders may watch for any change in voting power or a Schedule 13D that would indicate active engagement; the current form provides no such qualifier.

Key Figures

Beneficial ownership: 15,768,897 shares Percent of class: 6.1% Sole voting power: 12,377,523 shares +3 more

6 metrics

Beneficial ownership 15,768,897 shares reported in Schedule 13G

Percent of class 6.1% percent of common stock beneficially owned

Sole voting power 12,377,523 shares sole power to vote or direct the vote

Sole dispositive power 15,768,897 shares sole power to dispose or direct disposition

Reporting date 03/31/2026 ownership snapshot date

Signature date 04/22/2026 signed by Mike Yeates, CEO

Key Terms

Schedule 13G, Beneficially owned, Sole dispositive power

3 terms

Schedule 13G regulatory

"Item 1. | (a) | Name of issuer: Esperion Therapeutics Inc"

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

Beneficially owned financial

"Item 4. | Ownership (a) | Amount beneficially owned: 15,768,897"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

Sole dispositive power financial

"(iii) Sole power to dispose or to direct the disposition of: 15,768,897"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Esperion Therapeutics Inc

(Name of Issuer)

COM

(Title of Class of Securities)

29664W105

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 29664W105

1

Names of Reporting Persons

Wasatch Advisors LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 12,377,523.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 15,768,897.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

15,768,897.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.1 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Esperion Therapeutics Inc
(b)	Address of issuer's principal executive offices: CORPORATION TRUST CENTER 1209 ORANGE ST, WILMINGTON, US-DE, 19801, US
Item 2.
(a)	Name of person filing: Wasatch Advisors LP
(b)	Address or principal business office or, if none, residence: 505 Wakara Way, 3rd Floor, Salt Lake City, 84108, United States
(c)	Citizenship: DELAWARE
(d)	Title of class of securities: COM
(e)	CUSIP Number(s): 29664W105
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 15,768,897
(b)	Percent of class: 6.1 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 12,377,523
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 15,768,897
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Wasatch Advisors LP

Signature:	Mike Yeates
Name/Title:	CEO
Date:	04/22/2026

FAQ

What stake does Wasatch Advisors report in Esperion (ESPR)?

Wasatch Advisors reports beneficial ownership of 15,768,897 shares, equal to 6.1% of Esperion's common stock. The filing lists sole voting power of 12,377,523 shares and sole dispositive power of 15,768,897 shares.

Does the Schedule 13G filing show voting authority for Wasatch Advisors in ESPR?

Yes. The filing shows sole power to vote for 12,377,523 shares. It separately reports dispositive power, indicating who can direct votes versus sales of the shares.

When was the Esperion Schedule 13G signed and by whom?

The filing excerpt is signed by Mike Yeates, CEO with a signature date of 04/22/2026. The cover data lists a reporting date of 03/31/2026 for the ownership snapshot.

Does this Schedule 13G indicate Wasatch Advisors is trying to control Esperion?

No control claim is made in the excerpt. It lists beneficial ownership and voting/dispositive powers but does not state any intent to control or solicit changes in management.

What is the CUSIP for Esperion common stock in this filing?

The CUSIP provided in the excerpt is 29664W105. This identifies the specific class of Common Stock referenced in the disclosure.